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Abstract
Dendritic cells (DCs) are capable of processing and presenting exogenous
antigens using MHC class I molecules. This pathway is called antigen cross-
presentation and plays an important role in the stimulation of naïve CD8+ T cells
for infectious and tumor immunity. Our previous studies in DC2.4 cells and bone
marrow-derived DCs revealed that exogenously added ovalbumin (OVA) is
processed through endoplasmic reticulum (ER)-associated degradation (ERAD)
for cross-presentation. In this study, we aimed to further confirm these results by
purification of the subcellular compartment in which exogenous antigens undergo
ERAD from homogenates of DC2.4 cells pretreated with biotinylated OVA
(bOVA). bOVA-containing vesicles were purified using streptavidin (SA)-
magnetic beads from cell homogenates and were found to contain ER chaperones
and ERAD components together with proteins for antigen presentation. In
purified microsomes, bOVA was retained in membranous fractions and degraded
by the ubiquitin proteasome system in presence reticulocyte lysates and ATP.
These results strongly suggested that DCs processed and degraded exogenous
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antigens through ERAD for cross-presentation in this purified subcellular
compartment.
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1. Introduction
Major histocompatibility (MHC) class I molecules are generally expressed on the
cell surface with short peptides generated from endogenous antigens by the
ubiquitin-proteasome system and function as immunological self markers [1]. This
mechanism of antigen processing and presentation in single cells is called direct
presentation [1]. MHC class I molecules associated with non-self antigens, such as
specific proteins from cancer cells or infectious agents, serve as non-self markers
[1, 2, 3]. Cytotoxic T lymphocytes (CTLs), which destroy these non-self cells by
recognizing non-self markers, are derived from naive CD8+ T cells after
appropriate stimulation by antigen presenting cells (APCs) harboring both with
specific antigen-MHC class I complexes and costimulatory molecules [4, 5]. In
APCs, antigens from non-self cells can be internalized and presented on MHC
class I molecules [6, 7, 8]. This process is a unique phenomenon among several
subsets of dendritic cells (DCs) [9, 10, 11, 12, 13], and is called cross-presentation
[6, 7, 8]. Cross-presentation, is a critical mechanism mediating immune responses
against non-self cells [14, 15, 16, 17, 18, 19, 20, 21, 22] and parasite-infected cells
[23] and can induce peripheral tolerance for self-antigens [8].
In recent years, accumulating evidence has shown that generation of antigenic
peptides for cross-presentation is dependent on the ubiquitin-proteasome system
[24, 25, 26, 27] and transporter-associated with antigen presentation (TAP) [28],
which is required for direct presentation through intracellular pathways [7, 8].
Several groups have described the molecular mechanisms of cross-presentation
through intracellular pathways [24, 25, 26, 27, 29]. Some of the above analyses
have suggested that cross-presentation occurs through specialized intracellular
compartments, such as the endoplasmic reticulum (ER)-phagosome [24, 29] and
ERgosome [25, 27]. After internalization of an antigen, only DCs are capable of
processing and presenting exogenous antigens on MHC class I molecules [24, 29,
30, 31, 32]. The superior ability of DCs to participate in cross-presentation is
largely attributed to their antigen-processing capacity by the ubiquitin-proteasome
system [32]. Therefore, in order to avoid lysosomal degradation of exogenous
antigens, DCs express low levels of lysosomal proteases [33] with protease
inhibitors [33] by harboring phagosomes with a high phagosomal pH [34, 35].
Retained antigens are then retrotransported into the cytosol [36], possibly mediated
by Sec61 translocon [28, 38], and are processed through the ubiquitin-proteasome
system [28, 38]. Peptides transported into the ER by TAP can then be loaded onto
MHC class I molecules [24, 29].
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Misfolded and damaged proteins are harmful to cells and are therefore destined for
rapid degradation [39, 40, 41]. In the cytoplasm, unfolded proteins are degraded by
the ubiquitin-proteasome system. In the ER, proteins with defects in folding,
assembly, and glycosylation are recognized and retrograde-transported to the
cytoplasm by the ER-associated degradation (ERAD) system, followed by
degradation through the ubiquitin-proteasome system [42, 43, 44]. In both
pathways, the generated antigenic peptides undergo direct presentation on MHC
class I molecules [45, 46, 47, 48]. As shown previously, retrotransport and
degradation of endogenous antigens in intracellular pathways occur via a system
similar to that of ERAD [28, 38]. However, it is still unclear how exogenous
antigens are recognized by the ERAD system.
In this study, we investigated the mechanisms for processing of exogenous
antigens by intracellular degradation systems using purified exogenous antigen-
containing vesicles and in vitro reconstruction of ERAD for cross-presentation.
Our data provide important mechanistic insights into the recognition of exogenous
antigens by ERAD.
2. Material and methods
2.1. Cell culture
DC2.4, a DC line [49], was provided by Dr. K. L. Rock (Dana-Farber Cancer
Institute, Boston, MA, USA). Cells were cultured in RPMI-1640 (Sigma, St. Louis,
MO, USA) supplemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, 100 U/mL penicillin-streptomycin, 55 mM 2-mercap-
toethanol, 10 mM HEPES (pH 7.5), and 10% fetal calf serum (FCS) at 37 °C in 5%
CO2 unless otherwise indicated. Polymyxin B (50 mg/mL) was added to all cell
cultures.
2.2. Antibodies and reagents
The antibodies used in this study were as follows: anti-BiP (rabbit; MBL), anti-
calreticulin (for immunoprecipitation: rabbit antibodies from Affinity BioRea-
gents, Golden, CO, USA; for western blotting: mouse antibodies from Stressgen,
Victoria, British Columbia, Canada), anti-caveolin 1 (mouse; BD Biosciences,
San Diego, CA, USA), anti-CHIP (for western blotting: rabbit antibodies as a gift
from Dr. K. Tanaka, Tokyo Metropolitan Institute of Medical Science, Tokyo,
Japan; and chicken antibodies as a gift from Mr. S. Seki, MBL, Ina, Japan), anti-
Flag (mouse; Sigma), anti-GM-130 (mouse; BD Biosciences), anti-Hsp70
(mouse; Stressgen), anti-KDEL (mouse; Stressgen), anti-LAMP-1 (rat; BD
Biosciences), anti-H–2 Kb (mouse; Serotec), anti-multi-ubiquitin (mouse; MBL),
anti-ovalbumin (OVA; rabbit; Polysciences, Warrington, PA, USA), anti-protein
disulfide isomerase (PDI; rabbit; Stressgen), anti-proteasome 20S subunit alpha 5
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(rabbit; Affinity Bio Reagents), anti-Rab5 (mouse; BD Biosciences), anti-Sec61α
(rabbit; Upstate Cell Signaling Solutions, New York, NY, USA), anti-TAP1
(goat; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TAP2 (goat; Santa
Cruz Biotechnology), anti-Tapasin (rabbit; Stressgen), and anti-VCP (for western
blotting: rabbit antibodies from BD Biosciences; for immunoprecipitation: goat
antibodies from Santa Cruz Biotechnology) antibodies. As secondary antibodies,
streptavidin (SA)-peroxidase conjugate (SA-HRP; Vector Laboratories, Burlin-
game, CA, USA), goat anti-rabbit IgG peroxidase conjugate (Zymed), goat anti-
mouse IgG peroxidase conjugate (Zymed), goat anti-Rat IgG peroxidase
conjugate (Zymed), and bovine anti-goat IgG peroxidase conjugate (Santa Cruz
Biotechnology) were used. OVA were biotinylated (bOVA) using a FluoReporter
Biotin-XX protein labeling kit (Molecular Probes, Eugene, OR, USA). On
average, bOVA contained 2 mol biotin per 1 mol OVA. Flag-tagged ubiquitin,
MG132, lactacystine, and chloroquine were purchased from Sigma. Reticulocyte
lysates (RLs) were purchased from Promega (Madison, WI, USA). Gels were
stained using a SilverQuest silver staining kit (Invitrogen, Carlsbad, CA, USA).
SA-magnetic beads were purchased from Novagen.
2.3. Preparation of microsome fractions
DC2.4 cells were incubated with bOVA (250 μg/mL) for 4 h, washed twice in
phosphate-buffered saline (PBS), resuspended in homogenization medium (0.25 M
sucrose, 1 mM EDTA, 10 mM HEPES-NaOH [pH 7.4]), and then disrupted by 10
strokes with a Dounce homogenizer. Unbroken cells and nuclei were removed by
centrifugation at 2,000 × g for 10 min twice. When indicated, 2.5 mg/mL bOVA
was added to control cell homogenates. The post nuclear supernatant was pelleted
at 100,000 × g for 45 min, and pellets were resuspended in homogenization
medium. Aliquots were incubated with or without 100 μg/mL trypsin (Sigma) in
the presence or absence of 1% Triton X–100 for 30 min at 37 °C.
2.4. Discharge of bOVA from microsomes and degradation of
bOVA
Microsomes from DC2.4 cells that had been incubated with bOVA were incubated
with or without a 50% volume of RL, ATP (3 mM), and the indicated inhibitors.
After incubation at 37 °C for 2 h, bOVA was recovered with SA-magnetic beads
and resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) followed by western blotting with SA-HRP.
2.5. Immunoprecipitation
Microsomes from DC2.4 cells that had been incubated with bOVA were incubated
with or without a 50% volume of RL, ATP (3 mM), and the indicated inhibitors.
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After incubation at 37 °C for 2 h, supernatants were collected by 100,000 × g for
45 min. Samples were pre-cleared with protein G sepharose (Amersham Pharmacia
Biotech) and incubated with anti-HSP70 antibodies for precipitation by Protein G.
Precipitated samples were analyzed by SDS-PAGE and western blotting.
2.6. In vitro ubiquitination of bOVA in vesicles
Microsomes from DC2.4 cells that had been incubated with bOVA were incubated
with or without a 50% volume of RL and 0.2 pM Flag-tagged ubiquitin. After
incubation at 37 °C for 2 h, bOVA was recovered with SA-magnetic beads and
resolved by SDS-PAGE followed by western blotting.
2.7. Purification of microsomes in which bOVA was undergoing
ERAD
Microsomes from DC2.4 cells that had been incubated with bOVA at 37 °C for 2 h
were incubated with or without SA-magnetic beads (Novagen) at room temperature
for 30 min. Bead-bound vesicles were thus purified and used for further
experiments. Isolated vesicles from cells incubated with or without bOVA were
solubilized in TNE (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.5 M EDTA, 1%
Nonidet P-40). Portions of solubilized proteins were resolved on 7.5–15% SDS-
PAGE and transferred to Immobilon P membranes for western blotting. Protein
bands were visualized by chemiluminescence.
3. Results
3.1. Degradation of exogenously added bOVA in microsomes
We previously found that exogenously added bOVA was accumulated in
membranous compartments and processed through ERAD for cross-presentation.
Therefore, in this study, we first analyzed the in vitro reconstitution of the ERAD
system using exogenously added antigens, microsomes, and RLs. Microsomes
were prepared from DC2.4 cells pretreated with bOVA. bOVA that was recovered
in the microsomal fraction was resistant to trypsin but could be degraded after
addition of TX100, indicating that bOVA was accumulated in membranous
compartments as BiP (Fig. 1A). The bOVA found in microsomes was degraded in
the presence of the RL, and addition of ATP accelerated degradation, indicating
that this processing mechanism was energy dependent (Fig. 1B, C). Moreover,
degradation occurred as a function of chase time dependent on RL and was blocked
by the proteasome inhibitors MG132 and lactacystine but not by the lysosome
inhibitor chloroquine (Fig. 1D, E). In contrast, when bOVA was added after
fractionation, the protein was stable and was not degraded, regardless of the
addition of RL (Fig. 1D, E). After incubation at 37 °C for 1 h, about 40% of bOVA
was still associated with microsomes; however, significant amounts of bOVA were
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Fig. 1. In vitro reconstitution of retrotransport and degradation using OVA in microsomes (A),
Microsomes with (+) or without (−) prior addition of bOVA were treated with (+) or without (−)
trypsin and Triton X–100 (TX100). Proteins (2 μg) were resolved on 7.5–15% SDS-PAGE and
subjected to western blotting with the indicated antibodies. (B), Microsomes with (+) or without (−)
prior addition of bOVA were treated with (+) or without (−) RL and ATP for 1 h. Proteins (2 μg) were
subjected to western blotting with SA-HRP. Asterisks in the right indicate non-specific bands with SA-
HRP. Equivalent results were attained at least three independent assays. (C), Quantification of the
results shown in (B). Bars, mean ± S.D. (error bars) of three independents experiments. Student's test
was used to compare (bOVA + RL − ATP −) sample with (bOVA + RL + ATP −) sample, (bOVA +
RL − ATP +) sample, and (bOVA + RL + ATP +). **, ρ < 0.01, *,ρ < 0.1, NS, not significant, n = 3.
(D), Microsomes with prior addition of bOVA were treated with RL, ATP, and the indicated inhibitors:
MG132 (MG: 10 μM), lactacystine (LC: 2 μM), and chloroquine (CQ: 10 μM). Microsomes without
prior addition of bOVA were incubated with 2.5 μg of bOVA after fractionation (after) and were treated
with RL and ATP. Proteins (2 μg) were subjected to western blotting with SA-HRP. (E), Quantification
of the results shown in (D). Bars, mean ± S.D. (error bars) of three independents experiments. Student's
test was used to compare (Before, RL + reagent −) sample with (Before RL + reagent +) samples and
(After, RL − reagent −) sample with (After, RL + reagent −) sample. *, ρ < 0.01, NS, not significant, n
= 3. (F), Microsomes with (+) or without (−) prior addition of bOVA were treated with (+) or without
(−) RL in presence of ATP and MG132 (10 μM) for 1 h. Samples were then separated into supernatants
and pellets by centrifugation at 100,000 × g for 45 min. Proteins (2 μg) were subjected to western
blotting with SA-HRP. Asterisks in the right indicate non-specific bands with SA-HRP. To show the
band of bOVA in lane 4, exposure time of this figure is longer than Fig. 1B, results in enhancements of
non-specific bands with SA-HRP. Equivalent results were attained at least three independent assays.
(G), Microsomes with (bOVA before +) or without (bOVA before −) prior addition of bOVA were
treated with RL and ATP in presence or absence of and MG132 (10 μM) for 1 h. Samples without prior
addition of bOVA (bOVA before −) were added with 1.0 mg/mL bOVA (bOVA after +) or the same
volume of PBS (bOVA after −). Supernatants were subjected to immunoprecipitation (IP) with anti-
Hsp70. After SDS-PAGE, blotting was performed with SA-HRP and anti-HSP70. Equivalent results
were attained at least three independent assays. Full versions of all sliced images are provided in the
Supplementary Figures.
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released from microsomes, transported outside of microsomes, and recovered in
supernatants in the presence of RL (Fig. 1F). Released bOVA were coimmuno-
precipitated with cytosolic molecular chaperone, Hsp70 (Fig. 1G). These results
indicated that exogenously added bOVA accumulated in membranous compart-
ments and was then transported outside of microsomes, unfolded and degraded by
proteasomes in an energy-dependent manner. Therefore, exogenously added
bOVA was processed through an ERAD-like protein degradation mechanism.
3.2. In vitro ubiquitination of exogenously added bOVA in
microsomes
Next, we analyzed in vitro ubiquitination of bOVA in microsomes using Flag-
tagged ubiquitin. Microsomes with bOVA were incubated with or without RLs and
Flag-tagged ubiquitin. After incubation at 37 °C for 2 h, bOVA was recovered with
SA-magnetic beads and resolved by SDS-PAGE followed by western blotting. The
majority of bOVA in microsomes showed the same molecular mass as intact
bOVA (Fig. 2A). In addition, significant amounts of bOVA were polyubiquiti-
nated, as shown by western blotting with anti-Flag antibodies in the presence of
RLs and Flag-Ub (Fig. 2A). The amounts of polyubiquitinated bOVA shown in
[(Fig._2)TD$FIG]
Fig. 2. In vitro reconstitution of ubiquitination using OVA in microsomes (A), Microsomes with prior
addition of bOVA were treated with (+) or without (−) RL and Flag-tagged ubiquitin (Flag-Ub) for 1 h
and were then solubilized with TNE (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.5 M EDTA, 1%
Nonidet P-40). bOVA was purified with SA-magnetic beads and subjected to western blotting with the
indicated antibodies. Asterisks in the right indicate non-specific bands with SA-HRP. Equivalent results
were attained at least three independent assays. (B), Microsomes with prior addition of bOVA were
treated with (+) or without (−) RL, Flag-Ub, and MG132 for 1 h and solubilized using TNE. bOVA was
purified with SA-magnetic beads and subjected to western blotting with SA-Flag. Equivalent results
were attained at least three independent assays. Full versions of all sliced images are provided in the
Supplementary Figures.
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smear bands increased after the addition of MG132 in the presence of RLs and
Flag-Ub (Fig. 2B). These results also suggested that bOVA underwent ERAD-like
protein degradation; accumulated in microsomes, retro-transported out of
microsomes, ubiqutinated, and then degraded by proteasomes.
3.3. Purification of microsomes containing bOVA
Because exogenously added antigens appeared to be processed through an
ERAD-like mechanism, we hypothesized that bOVA in microsomes would
undergo translocation dependent on association with membranes via tranlocons,
such as Sec61 (Fig. 3A). Because membrane-associated bOVA specifically binds
with SA, we purified microsomes containing bOVA using SA-magnetic beads.
Microsomes from DC2.4 cells that had been incubated with bOVA were
incubated with or without SA-magnetic beads. After incubation at room
temperature for 30 min, SA-bound vesicles were isolated using magnetic beads.
Microsomes recovered using SA-magnetic beads were resolved by SDS-PAGE
followed by silver staining (Fig. 3B, D, F) and western blotting with SA-HRP
(Fig. 3C). bOVA was detected in purified vesicles in the presence of exogenously
added bOVA and SA-magnetic beads (Fig. 3C). As shown in Fig. 3B, nonspecific
proteins appeared to bind with SA-magnetic beads with or without bOVA. In
addition to these proteins, we found several unique proteins that appeared only in
the presence of exogenously added bOVA and SA-magnetic beads. Addition of
free bOVA before incubation with SA-magnetic beads to compete with SA
inhibited the purification of both specific and nonspecific proteins (Fig. 3D),
indicating that the purification of these proteins was dependent on membrane-
associated bOVA. We further confirmed this competition with bOVA by western
blotting with SA-HRP (Fig. 3E). Treatment with trypsin before addition of SA-
magnetic beads also prevented the purification of microsomes (Fig. 3F),
indicating that microsome purification depended on the presence of membrane-
associated proteins. The results of bOVA purification following trypsin treatment
were also confirmed by western blotting with SA-HRP (Fig. 3G). Collectively,
our results showed that purification of microsomes was dependent on membrane-
associated bOVA (Fig. 3A).
3.4. In vitro ubiquitination of bOVA by purified vesicles
The bOVA in purified microsomes was degraded in the presence of RLs in a
time-dependent manner, and this degradation event was blocked by MG132 and
lactacystine but not by chloroquine (Fig. 4A, B) as un-purified microsomes
(Fig. 1D). Therefore, we next analyzed the in vitro ubiquitination of bOVA in
purified microsomes using Flag-Ub to confirm the accomplishment our
purification. After incubation at 37 °C for 2 h with Flag-Ub, bOVA was
polyubiquitinated in purified microsomes in the presence of RLs and Flag-Ub
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(Fig. 4C). The amounts of polyubiquitinated bOVA were augmented in the
presence of MG132 (Fig. 4D). These results suggested that purified microsomes
contained ERAD machinery proteins.
[(Fig._3)TD$FIG]
Fig. 3. Purification of microsomes with bOVA undergoing ERAD (A), Schematic model of purification
of microsomes with bOVA undergoing ERAD. bOVA is associated with the membrane through the
Sec61 translocon and targeted with SA-magnetic beads. (B), Microsomes with (+) or without (−) prior
addition of bOVA were purified with (+) or without (−) SA-magnetic beads. Proteins (2 μg) or
corresponding volumes of purified proteins were resolved on 7.5–15% SDS-PAGE, and silver staining
was used to visualize protein bands. Triangles on the right side indicate nonspecific proteins binding to
the SA-magnetic beads. Triangles with asterisks indicate unique proteins found only in the presence of
exogenously added bOVA and SA-magnetic beads. Arrow indicates bOVA. P.N., post nuclear fraction.
Asterisks in the right indicate non-specific bands with SA-HRP. Equivalent results were attained at least
three independent assays. (C), Western blotting results of the samples shown in (B) using SA-HRP.
Equivalent results were attained at least three independent assays. (D), Microsomes with prior addition
of bOVA were purified with (+) or without (−) SA-magnetic beads after addition of 2.5 mg/mL bOVA
(+) or the same volume of PBS (−). Proteins (2 μg) or corresponding volumes of purified proteins were
resolved on 7.5–15% SDS-PAGE, and silver staining was used to visualize protein bands. Equivalent
results were attained at least three independent assays. (E), Western blotting results of the samples
shown in (D) using SA-HRP. Equivalent results were attained at least three independent assays. (F),
Microsomes with prior addition of bOVA were purified with SA-magnetic beads. Microsomes were
treated with (+) or without (−) trypsin and TX-100 before purification (left two lanes) or after
purification (right two lanes). Proteins (2 μg) or corresponding volumes of purified proteins were
resolved on 7.5–15% SDS-PAGE, and silver staining was used to visualize protein bands. Triangles on
the right side indicate nonspecific proteins binding to the SA-magnetic beads. Triangles with asterisks
indicate unique proteins found only in the presence of exogenously added bOVA and SA-magnetic
beads. Equivalent results were attained at least three independent assays. (G), Western blotting results
of the samples shown in (F) using SA-HRP. Equivalent results were attained at least three independent
assays. Full versions of all sliced images are provided in the Supplementary Figures.
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3.5. Proteins associated with purified microsomes
To confirm that purified microsomes were not part of the conventional ER but
were specialized compartments, we used western blotting with specific antibodies
to detect the presence of ER-associated proteins. bOVA was only detected in
bOVA-positive purified microsomes (Fig. 5A). Four ER resident proteins, i.e.,
PDI, Sec61-α, calreticulin, and GP96, were specifically associated with purified
microsomes (Fig. 5B). Molecules for antigen processing and presentation, such as
CHIP, VCP, proteasomes, MHC class I H–2 Kb, TAP1, TAP2, and Tapasin, were
also associated with purified microsomes (Fig. 5C, D). Copurification of the
endosome/lysosome-specific proteins Rab5 and LAMP1 (Fig. 5E) suggest that
[(Fig._4)TD$FIG]
Fig. 4. In vitro reconstitution of degradation and ubiquitination using OVA in purified microsomes (A),
Purified microsomes were treated with RL, ATP, and the indicated inhibitors. Proteins (2 μg) were
subjected to western blotting with SA-HRP. Equivalent results were attained at least three independent
assays. (B), Quantification of the results shown in (A). Student's test was used to compare (Before, RL
+ reagent −) sample with (RL + reagent +) samples. *, ρ < 0.01, NS, not significant, n = 3. (C),
Purified microsomes with (+) or without (−) prior addition of bOVA were treated with (+) or without
(−) RL and Flag-Ub for 1 h and were solubilized using TNE. bOVA was purified with SA-magnetic
beads and subjected to western blotting with the indicated antibodies. Asterisks in the right indicate
non-specific bands with SA-HRP. Equivalent results were attained at least three independent assays.
(D), Purified microsomes were treated with (+) or without (−) RL, Flag-Ub, and MG132 for 1 h and
were then solubilized using TNE. bOVA was purified with SA-magnetic beads and subjected to western
blotting with SA-Flag. Asterisks in the right indicate non-specific bands with SA-HRP. Equivalent
results were attained at least three independent assays. Full versions of all sliced images are provided in
the Supplementary Figures.
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purified microsomes were not conventional ER vesicles but were specialized
compartments including both ERAD proteins and endosome/lysosome proteins. In
contrast, proteins found in the caveosome and Golgi apparatus, such as caveolin1 and
GM-130, were not detected by specific antibodies in purified microsomes (data not
shown). To identify proteins in purified microsomes, we employed two-dimensional
difference gel electrophoresis (DIGE). We separated proteins from purified
microsomes with bOVA and control microsomes without bOVA on two-dimensional
gels and then performed silver staining of the separated proteins. From these data, we
[(Fig._5)TD$FIG]
Fig. 5. Proteins in purified microsomes. (A–E), Proteins (2 μg) from purified microsomes with (+) or
without (−) prior addition of bOVA were subjected to western blotting with the indicated antibodies.
Equivalent results were attained at least three independent assays. (F), Proteins (10 μg) from purified
microsomes without (−) prior addition of bOVA were resolved by two-dimensional DIGE. Silver
staining was used to visualize protein spots. Triangles on the right side indicate nonspecific proteins
binding to the SA-magnetic beads. Equivalent results were attained at least three independent assays.
(G), Proteins (10 μg) from purified microsomes with (+) prior addition of bOVA were resolved by two-
dimensional DIGE. Silver staining was used to visualize protein spots. Triangles on the right side
indicate nonspecific proteins binding to the SA-magnetic beads. Triangles with asterisks indicate unique
proteins found only in the presence of exogenously added bOVA and SA-magnetic beads. Equivalent
results were attained at least three independent assays. (H), The silver stained image of purified
microsomes with (+) prior addition of bOVA was pseudo-colored green (Fig. 5F), and that of control
microsomes without (−) prior addition of bOVA was pseudo-colored red (Fig. 5G). Triangles on the
right side indicate nonspecific proteins binding to the SA-magnetic beads. Triangles with asterisks
indicate unique proteins found only in the presence of exogenously added bOVA and SA-magnetic
beads. The two images were merged. A black arrow indicates BiP, and a dotted arrow indicates actin.
Full versions of all sliced images are provided in the Supplementary Figures.
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searched for proteins that were only present in purified microsomes (Fig. 5F–H). As
shown in Fig. 5H, we found many protein spots unique to bOVA-containing purified
microsomes (Fig. 5A–E) and two large proteins spots representing nonspecific
proteins bound to SA-magnetic beads. These latter two proteins were found to be
actin and BiP (data not shown). The unique proteins are now being identified and
examined in our laboratory.
4. Discussion
Processing and presentation of exogenous antigens on MHC class I molecules is
called antigen cross-presentation. In cross-presentation through the intracellular
pathway, exogenous antigens are incorporated by endocytosis, accumulated in ER-
like compartments, and retrotransported through the Sec61 complex to the cytosol
where they are polyubiquitinated and degraded by the ubiquitin-proteasome system
[28, 38]. The latter half of this machinery, i.e., retrotransport and ubiquitin-
dependent degradation of exogenous antigens, employs the protein quality control
system in the ER, called ERAD. These latter steps require driving forces provided
by hydrolyses ATP, retrotransport, polyubiquitination, and Ubiquitin-dependent
degradation by the proteasome. However, no previous studies had examined
whether exogenous antigens accumulated in conventional ER vesicles or in
specialized microsomes for cross-presentation and how exogenous antigens are
recognized as substrates for ERAD.
In this report, we purified microsomes containing exogenously added OVA and
reconstituted the ERAD-dependent degradation of exogenously added OVA in
purified microsomes in vitro. Exogenously added OVA accumulated in
microsomal fractions and were degraded in a time-dependent manner in the
presence of RLs and ATP. This degradation of OVA was inhibited by proteasome
inhibitors but not by a lysosome inhibitor, indicating that bOVA was processed by
proteasomes. Requirements of ATP for degradation of OVA also support our
hypothesis; exogenously added OVA were processed by proteasomes. We also
found that some portion of exogenous OVA was retrotransported to outside of
microsomes and associated with Hsp70 in the presence of RLs. The amounts of
bOVA associated with Hsp70 were augmented by addition of the proteasome
inhibitor suggesting that bOVA was unfolded after retro-translocation to cytosol
before degradation by proteasomes.
We also reconstituted ubiquitination of exogenous OVA in the presence of RLs.
These ubiquitination was only detected by anti-Flag antibody, but not by neither
SA-HRP nor anti-OVA antibody. Since considerable amounts of bOVA
incorporated into microsomes was ubiqutinated before fractionation, we could
not distinguish these two kinds of bOVA, one was ubiqutinated before
fractionation and another was ubiqutinated after addition of Flag-Ub both by
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SA-HRP and anti-OVA antibody. Addition of MG132 enhanced smear bands
detected by anti-Flag antibody indicating that those smear bands were results of in
vitro ubiqutination by Flag-Ub.
After retrotransport to the cytosol, OVA was ubiquitinated and then degraded by
proteasomes in the presence of RLs and ATP, demonstrating that the latter half of
the cross-presentation pathway was reconstituted and that the exogenously
incorporated OVA could be recognized as a substrate for ERAD. Since Hsp70
facilitates ERAD substrate selection and targeting [37], coprecipitation of
exogenous OVA added before fractionation with Hsp70 also supports our
hypothesis. However, when OVA were added after fractionation, it did not
localize to the microsomes and was not degraded efficiently. Since conventional
ERAD substrates are misfolded proteins that have failed to fold properly in the ER,
exogenous OVA added before fractionation should be unfolded after endocytosis.
In addition to the above results, four lines of evidence also support the unfolding of
incorporated OVA: 1) the bOVA used in this study was soluble and showed
equivalent cross-presentation efficiency with normal nonbiotinylated OVA [38]; 2)
exogenous bOVA added before solubilization of cells but after solubilization was
associated with several ER resident molecular chaperones [38]; 3) OVA, a member
of the albumin family of proteins, has a highly conserved globular structure and is
soluble in water [50]; 4) serum albumin has a molecular chaperone-like role,
associating with extracellular unfolded proteins and inhibiting their aggregation
[51]. Therefore, exogenous OVA were unfolded after endocytosis in the
microsome fraction, allowing it to be recognized as a substrate for the ERAD
machinery; and 5) since bOVA neither degraded nor associated with Hsp70 when
OVA was added after fractionation, the only addition of RLs on native OVA never
influence upon the folding of this protein.
We and other groups previously reported that exogenous antigens are localized in
both the ER and endosomes in DCs [28, 38, 52]. However, these studies did not
clarify the cellular fractions in which exogenous antigens undergo ERAD.
Therefore, in the current study, we purified microsomes in which exogenous
antigens were transported across membranes. We hypothesized that exogenous
antigens associated with the membrane via translocons, such as Sec61. Using
bOVA as an exogenous antigen, we purified microsomes with SA-magnetic beads.
Our results identified several unique proteins that were purified in the presence of
both bOVA and SA. Competition with free bOVA and digestion of membranous
bOVA with trypsin inhibited the purification of these proteins, indicating that SA
targeted membrane-associated bOVA, consistent with our hypothesis. From these
purified microsomes, we reconstructed the proteasome-dependent ubiquitination
and degradation of bOVA in vitro, supporting the hypothesis that ERAD occurred
to promote cross-presentation of exogenous antigens in specialized compartments.
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The purified microsomes contained both ER resident proteins and endosome/
lysosome-specific proteins, suggesting that purified microsomes showed specific
features of both the ER and endosomes/lysosomes. In contrast, proteins from other
membranous fractions, such as caveosomes and the Golgi apparatus, were not
purified, indicating that non-specific membranous fractions were not included in
these purified microsomes. In addition to these membranous proteins, cytosolic
proteins involved in antigen processing were purified in the isolated microsomes.
Those purified proteins included a set of machinery for cross-presentation,
retrotransport, ubiquitination, and processing of extracellular antigens and
transport and loading of antigenic peptides on MHC class I molecules, indicating
that ERAD and antigenic peptide loading occurred in these purified microsomes
and suggesting that purified microsomes were specific for cross-presentation. In
addition, the purified microsomes contained more than 100 unique proteins, which
are now being experimentally examined in our laboratory. However as shown in
Fig. 5H, BiP non-specifically bounds with SA-magnetic beads, indicating a small
amounts of ER derived vesicle purified non-specifically by our purification
methods. But the amounts of those non-specific proteins, such as PDI, BiP, and
Calreticulin, are low enough compared with their positive controls. Essentially
these non-specifically purified vesicles showed neither ubiquitination nor
degradation against extra added bOVA after purification (data not shown).
DCs have the capacity for cross-presentation in order to efficiently destroy non-self
cells, such as cancer cells or virus-infected cells. Although this process requires
rapid degradation of endogenous antigens, properly folded endogenous antigens
will not degraded promptly; the half-life of properly folded viral antigens is
sufficiently long to escape direct presentation. As shown previously and in this
report, endogenously added OVA was associated with ER resident molecular
chaperones and degraded by ERAD, indicating that OVA was unfolded in DCs
[38]. In Herpes simplex virus (HSV)-infected cells, proteins containing disulfide
bonds from can be digested by gamma-interferon-inducible lysosomal thiolreduc-
tase (GILT), and unfolding of HSV proteins has been shown to be critical for cross-
presentation [53]. Because unfolded proteins in cells are harmful, cells rapidly
recognize and degrade unfolded proteins through the ubiquitin-proteasome system,
and the process of unfolding of extracellular antigens plays an essential role in this
rapid cross-presentation. Although DCs are known to use the ERAD system for
rapid cross-presentation, the process through which proteins are unfolded has still
not been clarified. In this report, we purified microsomes in which endogenous
antigens were degraded through the ERAD system. The proteins included in these
purified microsomes resembled proteins described in proteomic analyses of ER-
phagosomes [24, 29, 54] or ERgosomes [25, 27]. In these compartments, the ER
fuses with the plasma membrane, providing the required membrane and protein
machinery for cross-presentation [24, 25, 26, 27, 29, 53, 55, 56, 57]. In addition,
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our data suggested that the ER might function in the recognition of incorporated
antigens. Most proteins in endosomes are unfolded as the endosome matures; our
data suggested that some mature endosomes in DCs fuse with the ER. In mature
endosome exogenous antigens are unfolded, and after fusion with ER ER-resident
molecular chaperones recognize the unfolded proteins for effective EARD.
Proteomic analyses of the above-purified microsomes are needed in the future in
order to test this hypothesis.
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